Rising insulin prices drive jump in diabetes treatment costs: report

Higher insulin spending accounted for nearly half of a $6,000 jump in per-person spending for Type 1 diabetes care between 2012 and 2016.

By Les Masterson • Jan. 23, 2019

Walgreens pays $270M to settle Medicaid fraud allegations

For years, the U.S. government alleges, the pharmacy giant routinely submitted false data to improperly secure federal reimbursement for insulin pens not needed by patients.

By Suzanne Elvidge • Jan. 23, 2019

Explore the Trendline➔

Drug pricing

Drug pricing legislation has put pharmaceutical companies on the defensive and created a new precedent for the industry.

By BioPharma Dive staff

J&J sales forecast disappoints as generic, pricing headwinds rise

Still, the pharma predicts finding a path to growth in 2019, counting on drugs like Stelara, Darzalex and Tremfya. 

By Ned Pagliarulo • Jan. 22, 2019

Sandoz launches EpiPen rival at $250 per two-pack

The much-delayed launch has been a boost for originator Adamis Pharmaceuticals and provides a new competitor to the beleaguered EpiPen.

By Suzanne Elvidge • Jan. 18, 2019

7 biopharma trends to watch in 2019

Intensifying political pressure, surging cancer drug investment and the rise of pharma chief digital officers are among the factors which look set to shape the industry's next 12 months.

By Ned Pagliarulo • Jan. 17, 2019

Hospital drug spend spiked 19% from 2015-17, coalition says

The report, sponsored by hospital and pharmacy groups, is the latest attack in an ongoing battle over who should hold blame for high healthcare costs.

By Rebecca Pifer • Jan. 16, 2019

Congressional investigation targets Pfizer, Novartis and J&J, among others

The new House Oversight chairman has asked 12 pharmas for pricing info on 18 top drugs, as Congress prepares to further scrutinize the industry.

By Andrew Dunn • Jan. 15, 2019

Louisiana launching 'Netflix model' in Medicaid for hep C drugs

The state is looking for a pharmaceutical partner on a project that will cap state spending for the expensive liver disease treatments.

By Les Masterson • Jan. 14, 2019

The winners and losers from JPM 2019

A $8 billion buyout helped lift cancer biotechs, while prospects for fresh dealmaking underpinned a noticeably optimistic J.P. Morgan Healthcare Conference.

By Ned Pagliarulo , Jacob Bell • Jan. 11, 2019

NICE turns down Novartis' Aimovig, flagging clinical trial concerns

The most clinically important patients were excluded from studies, the reviewing committee concluded in its draft decision to not recommend U.K. coverage of the migraine drug.

By Andrew Dunn • Jan. 11, 2019

J&J raises prices as Dems introduce bills aimed at lowering drug costs

Drug pricing reform has bipartisan support, but that hasn't stopped pharma from enacting hikes — in part because such moves have been vital to growth.

By Jacob Bell • Jan. 11, 2019

Grassley to zoom in on drug pricing, insurance mergers as Senate panel chair

The new Republican chairman of the Senate Finance Committee laid out his agenda, including allowing cheaper drug imports from Canada.

By David Lim • Jan. 10, 2019

Patient visibility into out-of-pocket prescription costs takes on added importance in January

Now is the time for BioPharma companies to put plans in place to meet the challenges associated with price transparency.

Jan. 10, 2019

As pharmas revert to regular price hikes, Azar threatens action with 'fighting words'

The Health and Human Services Secretary praised Merck & Co., Gilead Sciences and Amgen by name Wednesday on Twitter before declaring the industry "must stop" raising list prices.

By Andrew Dunn • Jan. 9, 2019

Bluebird proposes installment plan for LentiGlobin gene therapy

The biotech company would receive further payments only if LentiGlobin keeps working, according to a payment idea the company rolled out Tuesday.

By Kristin Jensen • Jan. 9, 2019

Drugmakers open new year with price increases on dozens of medicines

Allergan, Biogen and Bristol-Myers were among the companies that raised list prices, suggesting criticism hasn't halted a return to "business as normal" for the industry.

By Ned Pagliarulo • Jan. 2, 2019

Gene therapy could be cost effective in SMA, but not at $4M

A report from ICER found Novartis' experimental Zolgensma could be more cost-effective than Biogen's Spinraza in treating spinal muscular atrophy.

By Ned Pagliarulo • Dec. 21, 2018

Alnylam CEO talks politics, gene therapy and not becoming Pfizer

John Maraganore, who also serves as chair of BIO, spoke with BioPharma Dive in a wide-ranging interview on some of the industry's most pressing issues.

By Andrew Dunn • Dec. 14, 2018

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Looming over clinical victories seen at ASH was a problematic question: How exactly will health systems pay for these powerful yet pricey therapies?

By Jacob Bell • Dec. 5, 2018

Bipartisan bill introduced in Senate to penalize pharma Medicaid gaming

The incoming leaders of the Senate Finance Committee want to set monetary penalties for drugmakers that misclassify products within Medicaid.

By Andrew Dunn • Dec. 5, 2018

Merck increased list prices on Keytruda, Gardasil in November

The pharmaceutical giant made a pricing pledge this summer. A company spokesperson contended these price hikes are "fully consistent" with the plan.

By Andrew Dunn • Nov. 29, 2018

Teva launches EpiPen generic at same price as Mylan's version

The copycat's entry could be a threat to Mylan, though limited supply may hamper the commercial impact. 

By Suzanne Elvidge • Nov. 28, 2018

CMS aims to tackle drug costs by giving payers more bargaining power

Under the agency's proposal, Part D plans would be allowed to exclude protected drugs from their formularies in certain instances. 

By Samantha Liss • Nov. 27, 2018

Luxturna cleared for sale in Europe, but payer support uncertain

Spark and commercialization partner Novartis now face the battle of getting the pricey gene therapy covered in Europe. 

By Suzanne Elvidge • Nov. 26, 2018

Kaleo under fire for price hikes on naloxone treatment

Kaleo raised its price for Evzio from $575 to $4,100 in fewer than three years. Now, the company's tactics are the focus of a new Senate report and a "60 Minutes" segment.

By Andrew Dunn • Nov. 19, 2018